

ERA-NET on Cardiovascular Diseases

Joint Transnational Call for Proposal 2017(JTC 2017):

"Mechanisms of early atherosclerosis and/or plaque instability in Coronary Artery Disease"

Full-proposal application form

All fields must be completed using "Arial font, size 11" characters, margins of 1.27 cm.

Please note that incomplete full-proposals, proposals using a different format or exceeding length limitations of any sections can be rejected without further review.

All the information requested in this document must be compiled into one single Pdf-document and uploaded to the electronic submission system. The information given in the pre-proposal is binding. Thus, any fundamental changes between the pre and full proposals, e.g. composition of the consortia, objectives of the project, or the budget must be communicated to the JCS with detailed justification and will only be allowed by the Call Steering Committee (CSC) under exceptional circumstances.



Basic project data

- 1.a Project Title
- 1.b Project acronym (max. 20 characters)
- 2. Duration of the project (months)
- 3. Total funding applied for (€) (please take the final requested budget from the electronic submission tool)
- 4. Sub-topic selection (please tick the box accordingly)

Exploration of mechanism leading to plaque instability	Improvement of imaging techniques as well as validation of biomarkers, leading to earlier recognition of risk and /or protective factors

- 5. Keywords Identify between three and seven keywords that represent the scientific content.
- **6. Abstract** Please give a comprehensive and readable summary of the primary aims and methods of the project. Please note that if your proposal is selected for funding this abstract could be used for communication purposes by ERA-CVD or national funding agencies (max. 1600 characters including spaces)
- 7. Consortium coordinator (Partner 1)

Family Name, first Name	
Name of Institution	
Department	
Position	
Address	
City, Country	
Type of entity	Academia, Clinical or Public Health, SME or Industry

8. Research Partners:

8a. Research partners asking for funding:

No.	City, Country	Research Partner (Principal investigator)	Institution, Department, full affiliations	Type of entity: Academia, Clinical or Public Health, SME and Industry
2				
3				
4				
5				



6	Only possible if partner is from Estonia, Latvia,	
0	Poland, Romania, Slovakia or Turkey	

8b. Associated research partner not asking for funding (one maximum):

No	City, Country	Research Partner (Principal investigator)	Institution, Department, full affiliations	Type of entity: Academia, Clinical or Public Health, SME and Industry

Project description

1. Background and present state of the art in the research field and preliminary results obtained by the consortium members (max. 2 pages)

2. Description of the aims (max. 1 page in total)

Aim No.	Description	Partner(s) responsible for the aim / workload
1		
2		
3		
4		
5		
6		

- 3. Workplan (max. 15 pages), it must contain:
 - Description of the working program including the objectives, the rationale and the methodology, highlighting the novelty, originality and feasibility of the project; please describe, if applicable, how you will pay attention to gender aspects¹;
 - Clearly defined responsibilities and workloads [expressed in person months] of each participating research partner, time plan, including project coordination and management;
 - References
 - Diagrams and figures

Please use the following table for detailing the distribution of work in person months (PM) in different work packages (WP) (adapt as necessary):

No.	Research Partner (principal investigator)	WP1 (PM)	WP2 (PM)	WP3 (PM)	WP4 (PM)	WP5 (PM)	WP6 (PM)	WPxx (PM)	SUM
1									
2									
3									

¹ Please click <u>here</u> for more information on how gender differences can be addressed.



SUM				

- **4. Diagram** which compiles the work plan, timeline, sequencing of work packages, the contribution of the partners to each work package and their interactions (Gantt chart, Pert or similar, max. 1 page)
- 5. Added value of the proposed transnational collaboration and the multidisciplinary expertise within this collaboration (max. 1 page)
- 6. Description of the unmet medical and patients' need and that are addressed by the proposed work, the potential health impact that the results of your proposed work will have and exploitation / dissemination of project results. Please carefully consider gender differences. (max. 1 page)
- 7. Description of patents and present / future position with regard to intellectual property rights, both within and outside the consortium (e.g. any barriers to sharing materials or translating the results into clinical application) (max. ½ page)
- **8.** Description of ongoing or submitted research grants of each participating partner related to the present topic (indicating funding sources [include at least: ID number, amount and duration of funded project; funding agency] and possible overlaps with the project proposed) (max. ½ page per research partner)
- **9. Ethical and legal issues according to national regulations if applicable** (e.g., research on humans, animals or biomaterials including stem cells, data protection, use of animals in accordance with the suggestions of the ARRIVE-Guidelines²) (max. ½ page)
- **10.** Possible interaction with European Infrastructure Initiatives should be named (where applicable, e.g. BBMRI, ELIXIR, EATRIS, EU-Openscreen, etc.) (max. ¼ page)
- 11. Description of participation/engagement of Industry and/or patient organizations within the proposal, including their role and contribution (max. 1 page, only if applicable)
- **12. Scientific justification of requested budget** (rational distribution of resources in relation to project's activities, partners responsibilities and time frame; please also specify co-funding from other sources necessary for the project if applicable) (max. ½ page per research partner)
- **13. Brief CV for each principal investigator** (once converted into Pdf document: *max. 1 page DIN-A4, Arial 11, single-spaced, margins of 1.27 cm per PI*) Please follow this format:

NAME DATE OF BIRTH POSITION TITLE

EDUCATION/TRAINING (Master, PhD, Clinical Specialization ... only mention Institution, Degree, Year, Field)

A. Positions and Honours

- 1. Positions and Employment
- Other Experience and Professional Memberships
- 3. Honours and awards

B. Publications

- 1. Number of publications: 1) total, 2) as first author and 3) as second last and last author
- 2. Best 5 selected peer-reviewed scientific publications, relevant for this proposal
- 3. Best 5 selected non-scientific publications, e.g. policy documents, guidelines or newspaper articles etc.

C. Research Support (over the last 10 years)

- 1. Ongoing Research Support
- 2. Completed Research Support

D. Activities on knowledge management (translation of results for the public, participation of patients in the research, etc.)

² The <u>ARRIVE Guidelines</u>: Animal Research: Reporting of In Vivo Experiments. Originally published in PLOS Biology, June 2010



14. Date and signature of the coordinator